Format

Send to

Choose Destination
J Obes. 2013;2013:610908. doi: 10.1155/2013/610908. Epub 2013 Dec 30.

Safety and efficacy of glucomannan for weight loss in overweight and moderately obese adults.

Author information

1
Rush University College of Nursing, 600 S. Paulina Street, Suite 1080, Chicago, IL 60612, USA.
2
Rush University Medical Center, 1725 W. Harrison Street, Chicago, IL 60612, USA.
3
Section of Gastroenterology and Nutrition, Rush University Medical Center, 1725 W. Harrison Street, Chicago, IL 60612, USA.
4
North Park University School of Nursing, 3225 W. Foster Avenue, Chicago, IL 60625, USA.
5
Community, Systems, and Mental Health Nursing, Rush University College of Nursing, 600 S. Paulina Street, Suite 1080, Chicago, IL 60612, USA.
6
Faculty Practice, Rush University College of Nursing, 600 S. Paulina Street, Suite 1080, Chicago, IL 60612, USA.

Abstract

BACKGROUND:

Few safe and effective dietary supplements are available to promote weight loss. We evaluated the safety and efficacy of glucomannan, a water-soluble fiber supplement, for achieving weight loss in overweight and moderately obese individuals consuming self-selected diets.

METHODS:

Participants were randomly assigned to take 1.33 grams of glucomannan or identically looking placebo capsules with 236.6 mL (8 ounces) of water one hour before breakfast, lunch, and dinner for 8 weeks. The primary efficacy outcome was change in body weight after 8 weeks. Other efficacy outcomes were changes in body composition, hunger/fullness, and lipid and glucose concentrations. Safety outcomes included gastrointestinal symptoms/tolerance and serum liver enzymes and creatinine levels.

RESULTS:

A total of 53 participants (18-65 years of age; BMI 25-35 kg/m²) were enrolled and randomized. The two groups did not differ with respect to baseline characteristics and compliance with the study supplement. At 8 weeks, there was no significant difference between the glucomannan and placebo groups in amount of weight loss (-.40 ± .06 and -.43 ± .07, resp.) or other efficacy outcomes or in any of the safety outcomes.

CONCLUSIONS:

Glucomannan supplements administered over 8 weeks were well tolerated but did not promote weight loss or significantly alter body composition, hunger/fullness, or lipid and glucose parameters. This trial is registered with NCT00613600.

PMID:
24490058
PMCID:
PMC3892933
DOI:
10.1155/2013/610908
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Hindawi Publishing Corporation Icon for PubMed Central
Loading ...
Support Center